Provided by Tiger Trade Technology Pte. Ltd.

Sionna Therapeutics

7.04
+0.16002.33%
Post-market: 7.050.0100+0.14%19:30 EDT
Volume:1.97M
Turnover:14.02M
Market Cap:316.79M
PE:-3.25
High:7.37
Open:6.95
Low:6.91
Close:6.88
52wk High:54.97
52wk Low:4.01
Shares:45.00M
Float Shares:16.73M
Volume Ratio:1.43
T/O Rate:11.78%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1683
EPS(LYR):-1.8835
ROE:-32.34%
ROA:-21.54%
PB:1.19
PE(LYR):-3.74

Loading ...

Analysts’ Opinions Are Mixed on These NA Stocks: HealthStream (HSTM), Inter Parfums (IPAR) and Sionna Therapeutics, Inc. (SION)

TIPRANKS
·
Yesterday

Sionna Therapeutics is Maintained at Neutral by Wedbush

Dow Jones
·
Sep 15

Analysts Offer Insights on NA Companies: Jack Henry & Associates (JKHY) and Sionna Therapeutics, Inc. (SION)

TIPRANKS
·
Sep 15

Wedbush Raises Price Target on Sionna Therapeutics to $6 From $5, Keeps Neutral Rating

MT Newswires Live
·
Sep 15

Stifel Nicolaus Keeps Their Hold Rating on Sionna Therapeutics, Inc. (SION)

TIPRANKS
·
Sep 15

Sionna Therapeutics Restructures to Focus on Dual Combination

TIPRANKS
·
Sep 15

Sionna Therapeutics to Cut 46% of Staff to Focus on Cystic Fibrosis Drug Development

Dow Jones
·
Sep 15

Sionna Therapeutics to reduce workforce by 46%

TIPRANKS
·
Sep 15

Sionna Therapeutics, - Board Approves Workforce Reduction of About 46% and Implements Cost-Saving Measures

THOMSON REUTERS
·
Sep 15

Sionna Therapeutics Announces Plans to Advance Sion-451 + Sion-2222 Dual Combination into Phase 2a Proof-of-Concept Trial

THOMSON REUTERS
·
Sep 15

Sionna Therapeutics Announces Plans to Advance SION-451 + SION-2222 Dual Combination into Phase 2a Proof-of-Concept Trial

GlobeNewswire
·
Sep 15

Vertex Has Multiple Portfolio Catalysts With Favorable Risk-Reward, RBC Says

MT Newswires Live
·
Aug 12

Why Sionna Therapeutics (SION) Is Down 90.9% After Ending SION-719 Add-On To Trikafta Therapy

Simply Wall St.
·
Aug 12

Sionna Therapeutics price target lowered to $5 from $38 at Freedom Broker

TIPRANKS
·
Aug 11

Sionna Therapeutics Cut to Neutral from Buy by BTIG

Dow Jones
·
Aug 11

Sionna Therapeutics, Inc. : Btig Cuts to Neutral from Buy

THOMSON REUTERS
·
Aug 11

Sionna Therapeutics, Inc. : Jonestrading Cuts to Hold Rating

THOMSON REUTERS
·
Aug 11

Small U.S. Stocks Decrease; Sionna Therapeutics Posts Biggest Loss

Dow Jones
·
Aug 11

Sionna Therapeutics downgraded to Hold from Buy at JonesResearch

TIPRANKS
·
Aug 11

Sionna Therapeutics: Hold Rating Maintained as Disappointing CF Data Drive Price Target Cut from $60 to $6

TIPRANKS
·
Aug 11